Odysight revenue collapses 96% to $82K as Iran conflict delays orders; burn accelerates
Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~2 min read
Key Changes
-
high
Q1 2026 revenue fell 96% year-over-year to $82K from $2.1M, driven by loss of Fortune 500 medical customer and geopolitical delays in vision-based predictive maintenance solutions tied to Iran conflict escalation.
MD&A: Quarterly Revenue verify on EDGAR → -
high
Operating loss widened 17% to $5.3M despite revenue collapse, as sales and marketing expense more than doubled to $962K amid enhanced global selling efforts and new workforce recruitment.
MD&A: Operating Loss & Sales Expense verify on EDGAR → -
high
Cash declined from $37.2M to $21.8M over twelve months despite February 2025 capital raise, reflecting elevated burn rate; accumulated deficit grew $18M to $68.2M.
MD&A: Cash and Accumulated Deficit verify on EDGAR →
2 more material changes plus the full narrative summary — create a free account to see the rest. Takes 30 seconds.
Partner
Trade ODYS commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 8, 2026 5:59 AM